Researchers identify susceptibility locus for lung cancer and age-dependent association with obesity using Golden Helix software.
Bozeman, MT (April 17, 2008) — Golden Helix, Inc. today announced that researchers at the University of Texas MD Anderson Cancer Center and SUNY Upstate Medical University et al. have published two separate whole genome association papers making significant discoveries in the fields of cancer and obesity research.
Citing Golden Helix’s HelixTree software, researchers at MD Anderson Cancer Center conducted a genome-wide association study to identify risk variants for lung cancer. Authors Christopher Amos et al. successfully identified and replicated a locus on chromosome 15, specifically the region of 15q25.1, associated with lung cancer. Nature Genetics published the paper titled, Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1, on April 2, 2008. ›› Read the paper.
In a separate study, researchers from SUNY Upstate Medical University et al. illustrate potential causes for the difficulty in replicating genetic association findings. In the paper, On the Replication of Genetic Associations: Timing Can Be Everything!, author Jessica Lasky-Su et al. indicate that the strength of a genetic effect can vary with age and make replications of association studies problematic. Researchers used Golden Helix PBAT Software, a family-based statistical analysis package, to identify and replicate an age-varying association between a SNP in ROBO1 and obesity in five of eight studies. The American Journal of Human Genetics published the paper on April 3, 2008. ›› Read the paper.
About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.